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Granuloma Faciale Effectively Treated with Topical 
Pimecrolimus
Granuloma faciale (GF) is a rare skin disorder with 
a chronic-relapsing course. Cutaneous lesions affect 
predominantly the face of middle-aged Caucasian 
men with characteristic reddish papules, nodules, or 
plaques; however, various atypical cases with unusu-
al morphology or extra facial involvement have been 
reported (1-3). Despite many treatment options, both 
surgical and medical, GF remains therapeutically re-
sistant and even if effective treatment is achieved, the 
condition often recurs. 
A 60-year-old woman was referred to our depart-
ment with skin lesions that appeared in spring of 
2008 and were resistant to topical antibiotic and cor-
ticosteroid treatment. There were no other subjective 
complains except for aggravation from sun exposure. 
Clinical examination revealed four erythematous 
plaques localized symmetrically on both sides of the 
nose, on the right cheek, and between the eyebrows 
(Fig. 1a). A wide range of differential diagnoses were 
taken into consideration, including: cutaneous lupus 
erythematosus, sarcoidosis, polymorphic light erup-
tion, Jessner-Kanof lymphocytic infiltration, and ery-
thema fixum. Hematological and biochemical blood 
investigations were within normal ranges, and the 
serology for Treponema (T.) pallidum and Borrelia (B.) 
burgdorferi and the ANA test were negative. The his-
tologic evaluation revealed diffuse hyperkeratosis, 
acanthosis, and a dense perivascular inflammatory 
infiltrate in the upper dermis, demarcated from the 
epidermis by a highly demonstrative Grenz zone. 
Polymorphous infiltrate of lymphocyte, neutrophils, 
eosinophils, and plasma cells was seen around the 
small- and middle-sized vessels in the papillary der-
mis (Fig. 1b). The patient was treated with chloro-
quine 250 mg po bid. and topical betamethasone val-
erate cream for three months. The lack of significant 
therapeutic response led us to switch treatment to 
topical 1% pimecrolimus cream, applied twice daily 
for a period of three months. A follow-up visit after six 
months showed visual improvement of highly satisfy-
ing cosmetic outcome (Fig. 2).
Granuloma faciale is a rare skin disease of un-
known etiology. The first case was reported by Wig-
ley in 1945 as “eosinophilic granuloma”, and was later 
named granuloma faciale by Pincus (4). A spectrum 
of exogenic and endogenic factors such as actinic 
exposure, trauma, allergy (1), an Arthus-like reaction, 
or light irradiation (5) have been suspected to trigger 
the disease. GF has been typically described in mid-
dle-aged white men, though it can occur in any gen-
der, race, or age group. Our case features GF changes 
in a middle-aged woman, which is a relatively rare 
phenomenon. 
GF clinical presentation is characterized with vari-
ously colored papules, nodules, or plaques, common-
ly elevated and soft. These lesions have a well-de-
fined border and may vary in size from a few millime-
ters to several centimeters, as in our patient. Lesions 
are situated almost exclusively on the face (2,3), but 
may rarely appear on the trunk, scalp, and extremi-
ties which has been termed extrafacial GF (1). GF le-
sions are generally symptomless but some patients 
may complain of tender itching, stinging, or burning 
sensations. 
Histological findings play a crucial role in con-
firming the clinical diagnosis. A Grenz zone of unin-
volved dermis located beneath the epidermis and a 
polymorphous infiltrate of lymphocytes, neutrophils, 
eosinophils, and occasionally mast cells are the most 
characteristic indications. Sometimes, leukocytoclas-
tic vasculitis can be observed, although this is often 
referred to as an epiphenomenon. With the chronifi-
cation of the process lesions may show considerable 
storiform fibrosis (7).
Even the pathophysiology of GF is unknown; 
more recent theories suggested that a proliferation 
of unknown T-cell lymphocytes cause IL-5 production 
and eosinophil hemotaxis to the lesional skin (6). Re-
cently, Cesinaro at al. reported a significant number 
of GF cases associated with an abnormal content of 
IgG4 plasma cells, proposing that GF might represent 
a localized form of IgG4-related sclerosing diseases. 
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This is supported by the obliterative vascular inflam-
mation and storiform sclerosis which are seen in all 
chronic GF cases (7). 
GF is resistant to treatment and many different 
medical strategies have been tried, both conserva-
tive or surgical. The surgical or destructive methods 
include: a simple excision, dermabrasion, electrosur-
gery, cryotherapy, argon, CO2, or 585-nm pulsed dye 
lasers. Scarring may occur with many of these thera-
peutic modalities. The pulsed-dye laser often leads to 
resolution without scarring, and is claimed to be the 
preferred surgical method (8). The medical therapeu-
tic options that have been tried and are reported to 
be effective include topical or intralesional cortico-
steroids, antimalarials as in our case, isoniazid, calcif-
erol, topical PUVA, and radiation therapy. Dapsone is 
the oral medication most frequently reported to be 
somewhat effective. Topical tacrolimus has been re-
ported to have a beneficial effect in at least 9 patients 
(2,3,9).
Pimecrolimus, which was our therapeutic choice, 
belongs to the ascomycin class of macrolactam im-
munosuppressives. These immunosuppressive drugs 
inhibit the calcineurin pathway T-cell activation by 
suppression of the release of numerous inflamma-
tory cytokines, thus interrupting the immuno-inflam-
matory cascade. A thorough literature review shows 
only one previous publication of GF treatment with 
topical 1% pimecrolimus cream (10), applied twice a 
day for two months. Herein, we confirm the beneficial 
effect of this therapeutic approach, which may sug-
gest pimecrolimus as an additional topical modality 
to treat GF.
In conclusion, we reported on a woman with clini-
cally and histologically verified GF, who was effective-
ly treated with 1% pimecrolimus cream. The follow-
up observations showed an excellent cosmetic result. 
Despite the unpredictable long-term outcome, we 
believe that pimecrolimus can be considered an ef-
fective therapeutic modality for non-invasive treat-
ment of GF.
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Figure 1a. Erythematous plaques on both sides of the 
nose, on the right cheek, and between the eyebrows 
in a 60 year-old patient with granuloma faciale.
Figure 1b. Acanthotic epidermis, demarcated with a 
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trate (hematoxylin and eosin, ×400). 





4. Pinkus H. Granuloma faciale. Dermatol 
1952;105:85-99. 
5. Chung WK, Park GH, Kim CH, Chang SE, Lee MW, 
Choi JH, et al. Keloidal granuloma faciale after 
CO2 laser treatment for melanocytic naevus. J Eur 
Acad Dermatol Venereol 2009;23:611-2.
6. Gauger A, Ronet C, Schnopp C, Abeck D, Hein R, 
Köhn FM. High local interleukin 5 production in 
granuloma faciale (eosinophilicum): role of clo-
nally expanded skin-specific CD4+ cells. Br J Der-
matol 2005;153:454-7.
7. Cesinaro AM, Lonardi S, Facchetti F. Granuloma 
faciale: a cutaneous lesion sharing features with 
IgG4-associated sclerosing diseases. Am J Surg 
Pathol 2013;37:66-73.
8. Fikrle T, Pizinger K. Granuloma Faciale treated 
with 595-nm pulsed dye laser. Dermatol Surg 
2011;37:102-4.
9. Pérez-Robayna N, Rodríguez-García C, González-
Hernández S, Sánchez R, Guimerá F, Sáez M. Suc-
cessful response to topical tacrolimus for a granu-
loma faciale in an elderly patient. Dermatology 
2009;219:359-60.
10. Eetam I, Ertekin B, Unal I, Alper S. Granuloma faci-
ale: Is it a new indication for pimecrolimus? A case 
report. J Dermatolog Treat 2006;17:238-40.
Lyubomir Dourmishev, Vessela Ouzounova-
Raykova, Valentina Broshtilova, Lyubka Miteva
Department of Dermatology and Venereology, 
Medical University, Sofia, Bulgaria
Corresponding author:
Assoc. Prof. Lyubomir Dourmishev, MD
Department of Dermatology and Venereology 
Medical University Sofia




Received: February 2, 2014
Accepted: September 1, 2014
Letter to the editor Acta Dermatovenerol Croat
     2014;22(4):305-307
